Intellia Therapeutics, Inc. (NTLA): who owns it and who trades it
As of Nov 16, 2026, NTLA insiders reported 19 open-market sales worth $2.3M and 1 purchase worth $1.4M in the last 12 months, with 5% of the sale value made under pre-set 10b5-1 plans. The largest seller was John M Leonard (CEO), with $1.5M. 6 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Intellia Therapeutics
From the latest filingsOverall: more selling than buying. Insiders and famous investors mostly sold. Funds mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns NTLA
326 funds and institutions reported NTLA shares worth $2.5B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is ARK Investment Management LLC with 12.1%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| ARK Investment Management LLC | 16.88M | 12.08% | $286M | +16% |
| BlackRock, Inc. | 15.41M | 11.03% | $261M | +27% |
| State Street Corp | 9.23M | 6.61% | $156M | +33% |
| Vanguard Portfolio Management LLC | 7.33M | 5.25% | $124M | +18% |
| D. E. Shaw & Co., Inc. | 6.44M | 4.61% | $109M | +12% |
| Vanguard Capital Management LLC | 6.03M | 4.31% | $102M | +19% |
| Two Sigma Investments, LP | 5.24M | 3.75% | $88.6M | +11% |
| FMR LLC (Fidelity) | 4.77M | 3.42% | $80.8M | +131% |
| Ra Capital Management, L.P. | 4.53M | 3.24% | $76.6M | – |
| Regeneron Pharmaceuticals, Inc. | 3.70M | 2.65% | $62.7M | No change |
| Geode Capital Management, LLC | 3.63M | 2.60% | $61.4M | +27% |
| Arrowstreet Capital, Limited Partnership | 3.28M | 2.35% | $55.5M | +135% |
| Amova Asset Management Americas, Inc. | 2.90M | 2.07% | $49M | +47% |
| Sumitomo Mitsui Trust Group, Inc. | 2.90M | 2.07% | $49M | +47% |
| Dimensional Fund Advisors LP | 2.60M | 1.86% | $44M | +12% |
| Goldman Sachs Group Inc | 2.26M | 1.62% | $38.3M | +39% |
| UBS Group AG | 2.15M | 1.54% | $36.4M | -20% |
| Voloridge Investment Management, LLC | 2.07M | 1.48% | $35M | +28% |
| Contrarius Group Holdings Ltd | 1.96M | 1.40% | $33.1M | +2% |
| Jupiter Asset Management Ltd | 1.85M | 1.32% | $31.3M | +4% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, NTLA insiders reported $1.4M of open-market purchases and $2.3M of sales. 5% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 2, 2026 | John M Leonard | CEO | Sale plan | 9,000 | $11.99 | $108K | Form 4 |
| Oct 2, 2026 | Michael P Dube | Vice president | Sale | 1,864 | $12.43 | $23.2K | Form 4 |
| Aug 21, 2026 | John M Leonard | CEO | Sale | 2,785 | $13.00 | $36.2K | Form 4 |
| Aug 20, 2026 | John M Leonard | CEO | Sale | 19,890 | $12.60 | $251K | Form 4 |
| Jul 22, 2026 | Edward J Dulac III | CFO | Sale | 8,111 | $11.25 | $91.2K | Form 4 |
| Jul 2, 2026 | Edward J Dulac III | CFO | Sale | 4,677 | $18.00 | $84.2K | Form 4 |
| Jul 1, 2026 | Michael P Dube | Vice president | Sale | 2,641 | $16.78 | $44.3K | Form 4 |
| Mar 2, 2026 | James Basta | Vice president | Sale | 1,211 | $13.78 | $16.7K | Form 4 |
| Mar 2, 2026 | Eliana Clark | Vice president | Sale | 607 | $13.78 | $8.4K | Form 4 |
| Jan 5, 2026 | John M Leonard | CEO | Sale | 34,146 | $9.21 | $314K | Form 4 |
| Jan 5, 2026 | Birgit C Schultes | Vice president | Sale | 8,508 | $9.21 | $78.4K | Form 4 |
| Jan 5, 2026 | James Basta | Vice president | Sale | 10,397 | $9.21 | $95.8K | Form 4 |
| Jan 5, 2026 | Fred E Cohen | Director | Purchase | 150,000 | $9.35 | $1.4M | Form 4 |
| Jan 5, 2026 | David Lebwohl | Vice president | Sale | 11,903 | $9.21 | $110K | Form 4 |
| Jan 5, 2026 | Eliana Clark | Vice president | Sale | 9,515 | $9.21 | $87.6K | Form 4 |
| Jan 5, 2026 | Edward J Dulac III | CFO | Sale | 6,379 | $9.21 | $58.8K | Form 4 |
| Jan 5, 2026 | Michael P Dube | Vice president | Sale | 2,989 | $9.21 | $27.5K | Form 4 |
| Dec 11, 2025 | John M Leonard | CEO | Sale | 5,355 | $9.59 | $51.4K | Form 4 |
| Dec 11, 2025 | John M Leonard | CEO | Sale | 32,832 | $9.47 | $311K | Form 4 |
| Dec 11, 2025 | John M Leonard | CEO | Sale | 49,959 | $9.49 | $474K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| John M Leonard | President and CEO, Director | – | $1.5M | Nov 2, 2026 |
| Fred E Cohen | Director | $1.4M | – | Jan 5, 2026 |
| Edward J Dulac III | EVP, Chief Financial Officer | – | $234K | Jul 22, 2026 |
| James Basta | EVP, General Counsel | – | $112K | Mar 2, 2026 |
| David Lebwohl | EVP, Chief Medical Officer | – | $110K | Jan 5, 2026 |
| Eliana Clark | EVP, Chief Technical Officer | – | $96K | Mar 2, 2026 |
| Michael P Dube | VP, Chief Accounting Officer | – | $95K | Oct 2, 2026 |
| Birgit C Schultes | EVP, Chief Scientific Officer | – | $78.4K | Jan 5, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
NTLA short interest
Very high short interest. 31.6% of NTLA shares are sold short: about 1 share in 3. Over the last 12 reports the number of shares short went down 14%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 44.36M NTLA shares were sold short, 31.6% of the shares outstanding, down 0.2% from the report before. At the average daily volume of 4.01M shares, buying them all back would take about 11.1 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 44.36M | 31.61% | -0% | 4.01M | 11.1 |
| Oct 15, 2026 | 44.44M | 31.71% | -1% | 6.89M | 6.5 |
| Sep 30, 2026 | 45.11M | 32.19% | -3% | 4.77M | 9.5 |
| Sep 15, 2026 | 46.68M | 33.31% | +6% | 3.31M | 14.1 |
| Aug 31, 2026 | 43.93M | 31.35% | -2% | 3.41M | 12.9 |
| Aug 14, 2026 | 44.88M | 32.03% | +2% | 3.41M | 13.2 |
| Jul 31, 2026 | 44.01M | 31.41% | -4% | 3.68M | 12.0 |
| Jul 15, 2026 | 45.78M | 32.76% | -7% | 4.69M | 9.8 |
| Jun 30, 2026 | 49.22M | 35.23% | -2% | 6.53M | 7.5 |
| Jun 15, 2026 | 50.32M | 36.01% | +4% | 6.74M | 7.5 |
| May 29, 2026 | 48.52M | 34.72% | -6% | 5.26M | 9.2 |
| May 15, 2026 | 51.85M | 37.11% | +19% | 6.76M | 7.7 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Intellia Therapeutics company events
Intellia Therapeutics filed 14 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Nov 5, 2026.
- Nov 5, 2026ResultsReleased financial results. Filing
- Sep 8, 2026AnnouncementAlso on September 8, 2026, the Company announced that the U.S. Food and Drug Administration has accepted the Biologics License Application for lonvoguran ziclumeran and granted the BLA Priority Review with a Prescription Drug User Fee Act target action date of March 10, 2027. Filing
- Sep 4, 2026AgreementIntellia Therapeutics, Inc. entered into a Credit Agreement with the lenders from time to time party thereto, and OrbiMed Royalty & Credit Opportunities V, LP, as administrative agent. Filing
- Aug 6, 2026ResultsReleased financial results. Filing
- Jun 15, 2026AnnouncementThe Company announced additional positive results from the global Phase 3 HAELO clinical trial of lonvoguran ziclumeran or “lonvo-z” (formerly NTLA-2002) for hereditary angioedema. Filing
- Jun 10, 2026VoteReported shareholder vote results. Filing
- May 11, 2026ResultsReleased financial results. Filing
- Apr 30, 2026AgreementIntellia Therapeutics, Inc. entered into an underwriting agreement with Jefferies LLC, Goldman Sachs & Co. LLC, and Citigroup Global Markets Inc., related to a public offering of 16,744,187 shares of common stock of the Company, par value $0.0001 per share at a price to the public of $10.75 per… Filing
- Apr 27, 2026AnnouncementIntellia announced positive topline results from the global Phase 3 HAELO clinical trial of lonvo-z in HAE. Lonvo-z is an in vivo CRISPR gene editing candidate that is designed as a one-time treatment, administered in an outpatient setting, to inactivate the kallikrein B1 gene to permanently lower… Filing
- Apr 10, 2026RulesChanged its bylaws or articles. Filing
- Mar 2, 2026AgreementIntellia Therapeutics, Inc. previously entered into an Open Market Sale Agreement, dated March 4, 2022, and amended on February 23, 2024 (as amended, the “Sales Agreement”) with Jefferies LLC with respect to an at-the-market offering program under which the Company may offer and sell, from time to… Filing
- Feb 26, 2026ResultsReleased financial results. Filing
- Jan 27, 2026AnnouncementIntellia announced that the U.S. Food and Drug Administration has removed the clinical hold on the investigational new drug application for the MAGNITUDE-2 Phase 3 clinical trial of nexiguran ziclumeran for patients with hereditary transthyretin amyloidosis with polyneuropathy. Filing
- Jan 9, 2026AnnouncementAs the Company reported on October 27, 2025, Grade 4 liver transaminases and increased total bilirubin were reported in a patient who was dosed with nexiguran ziclumeran in the MAGNITUDE trial of nex-z for the treatment of transthyretin amyloidosis with cardiomyopathy. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Intellia Therapeutics financials
Famous investors that hold NTLA
6 of the 50 well-known investors we track reported holding NTLA in their latest 13F filing. The largest position is Cathie Wood's, worth $192M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Cathie Wood · ARK Investment Management | Q3 2026 | 15.93M | $192M | 1.1% | -6% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 591,200 | $7.1M | 0.0% | -58% |
| Ray Dalio · Bridgewater Associates | Q3 2026 | 137,158 | $1.7M | 0.0% | New |
| Ken Griffin · Citadel Advisors | Q3 2026 | 128,041 | $1.5M | 0.0% | -22% |
| Israel Englander · Millennium Management | Q3 2026 | 102,128 | $1.2M | 0.0% | -79% |
| Paul Tudor Jones · Tudor Investment Corp | Q3 2026 | 56,631 | $683K | 0.0% | -52% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named NTLA in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 10, 2026 | STATE STREET CORPORATION | 13G | 5.6% |
| Nov 10, 2026 | STATE STREET CORPORATION | 13G | 5.6% |
Questions about Intellia Therapeutics, Inc. (NTLA) stock
Who owns the most NTLA stock?
The largest reported owner of Intellia Therapeutics, Inc. (NTLA) is ARK Investment Management LLC, with 12.1% of the company. In total, 326 funds and institutions reported holding NTLA at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are NTLA insiders buying or selling?
In the last 12 months, NTLA insiders reported 1 open-market purchase worth $1.4M and 19 sales worth $2.3M. The latest trade was on Nov 2, 2026. See every trade.
What is the short interest in NTLA?
As of Oct 30, 2026, 44.36M NTLA shares were sold short, 31.6% of the shares outstanding, down 0.2% from the report before. At the average daily volume of 4.01M shares, buying them all back would take about 11.1 trading days (days to cover). See the history.
Which famous investors hold NTLA?
6 of the 50 well-known investors we track reported NTLA in their latest 13F filing, including Cathie Wood, Jim Simons, Ray Dalio. The largest position is worth $192M. See all holders.
Executive pay
Intellia Therapeutics's chief executive was paid a total of $5.1M for the year ended Dec 31, 2025, down 67% from $15.3M the year before. In the last 12 months, Intellia Therapeutics's executives and directors bought $1.4M of stock on the open market and sold $2.3M.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.